Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting [Yahoo! Finance]
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
Pliant Therapeutics (PLRX) had its price target lowered by Canaccord Genuity Group Inc. from $4.00 to $3.00. They now have a "hold" rating on the stock.
Pliant Therapeutics (PLRX) had its "overweight" rating reaffirmed by Piper Sandler.
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results [Yahoo! Finance]